Welcome
Welcome!
I hope everyone had a great and relaxing summer and is ready to continue our incredible EPAD journey. The EPAD Longitudinal Cohort Study (LCS) is well under way and EPAD is extending its Trial Delivery Center Network beyond the wave 1 TDCs thereby greatly increasing its capacity to recruit research participants into the LCS. Also congratulations to our IMI sister project AMYPAD that officially kicked-off on October 1st. Work is already underway to set up the collaboration and incorporate amyloid PET imaging into the LCS.
In the meantime WP4 and the legal team are hard at work setting up the EPAD proof-of-concept framework, which you will hear all about in a special issue of the EPAD newsletter that will arrive in your mailbox in January 2017.
This electronic newsletter will be published quarterly and be accessible via the EPAD website (www.epad.org) and inform the Alzheimer community on EPAD’s main achievements, upcoming events as well as allow you to meet the scientists who make it all happen.
In this issue, we focus on EPAD’s recommendations for the detection of early preclinical Alzheimer’s Disease that were recently published by EPAD’s Clinical Endpoints Scientific Advisory Group. We also bring you highlights from the July 2016 AAIC EPAD symposium in Toronto and you can find out more about 2 of the EPAD collaborators, Karen Ritchie and Sean Knox.
We hope you enjoy this issue of the EPAD newsletter! Happy Reading!
Serge Van der Geyten
EPAD Coordinator